NÖNuriye Özdemir

Nuriye Özdemir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nuriye Özdemir has a total of 314 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Zinc Supplementation and Topical Clobetasol on the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction: The ZINCLO-HAND Study

    by Orhun Akdogan, Enes Yesilbas, Mesut Yılmaz, Fatma Keskin Uzundere, Ahmet Oruc, Ender Eren Ozcelik, Gorkem Turhan, Mehmet Kayaalp, Ilknur Deliktas Onur, Haydar Temizyurek, et al.

    Purpose: Regorafenib-induced hand-foot skin reaction (HFSR) is a common dose-limiting toxicity. We evaluated whether prophylaxis with oral zinc plus topical clobetasol is associated with lower clinically significant HFSR compared with either strategy alone. Methods: ZINCLO-HAND was a prospective, multicenter, pragmatic, nonrandomized comparative study across 13 oncology centers in Türkiye. Adults initiating regorafenib were managed at physician discretion with oral zinc, topical clobetasol propionate 0.05%, or the combination for 8 weeks. The primary end point was grade ≥2 HFSR within the prophylaxis period. Secondary end points included grade 3 HFSR, treatment modification, relative dose intensity, and patient-reported outcomes. Results: Of 179 enrolled patients, 156 were evaluable: zinc, n = 49; clobetasol, n = 52; combination, n = 55. Grade ≥2 HFSR occurred in 38.8%, 38.5%, and 16.4% of patients, respectively ( P = .016). In multivariable logistic regression adjusted for age, Eastern Cooperative Oncology Group performance status, tumor type, and initial regorafenib dose intensity, zinc monotherapy (adjusted odds ratio [OR], 3.37 [95% CI, 1.30 to 8.71]; P = .012) and clobetasol monotherapy (adjusted OR, 3.15 [95% CI, 1.26 to 7.88]; P = .014) were associated with higher odds of grade ≥2 HFSR versus combination prophylaxis. Median relative dose intensity was comparable across groups. HFSR-attributable treatment modification occurred in 30.6%, 28.8%, and 12.7% of patients, respectively. Conclusion: In this nonrandomized prospective cohort, zinc plus topical clobetasol was associated with lower clinically significant regorafenib-induced HFSR and fewer HFSR-attributable treatment modifications. These findings support consideration of combination prophylaxis in routine practice and warrant randomized confirmation.

  • Open Access

    Association between PhenoAge-assessed biological age and survival outcomes in solid tumor patients treated with immune checkpoint inhibitors

    by Tuba Uğur Tuzcu, Enes Yeşilbaş, Orhun Akdoğan, Kadriye Başkurt, Galip Can Uyar, Nuriye Özdemir, Ahmet Özet, Ozan Yazıcı, Ömür Berna Çakmak Öksüzoğlu, Osman Sütcüoğlu

    Background: Chronological age may influence immune function, but individuals of the same age may differ in biological aging. We evaluated the association between biological age and clinical outcomes in patients with solid tumors treated with immune checkpoint inhibitor monotherapy. Methods: This retrospective two-center study included 302 patients with advanced solid tumors receiving ICI monotherapy. Biological age was estimated using the Levine PhenoAge model. Age-adjusted biological aging (PhenoAgeAccel) was defined as the residual from regression of PhenoAge on chronological age. Survival outcomes were compared according to PhenoAgeAccel status. Results: The median age was 67 years; most patients had non–small cell lung cancer (78.5%) or renal cell carcinoma (18.5%). Median progression-free survival was 3.8 months (95% CI, 3.1–4.5) in patients with PhenoAgeAccel > 0, versus 7.7 months (95% CI, 5.6–9.7) in those with PhenoAgeAccel ≤ 0 ( p < 0.001). Median overall survival was 7.1 months (95% CI, 5.5–8.8) in patients with PhenoAgeAccel > 0, versus 20.4 months (95% CI, 15.1–25.8) in those with PhenoAgeAccel ≤ 0 ( p < 0.001). In multivariate analyses, PhenoAgeAccel remained an independent predictor of overall survival (HR = 2.19, 95% CI: 1.65–2.91; p < 0.001) and progression-free survival (HR = 1.93, 95% CI: 1.47–2.54; p < 0.001). Conclusion: Biological age was strongly associated with survival outcomes in patients receiving immune checkpoint inhibitor monotherapy. These findings require validation in prospective cohorts and may support the integration of biological age as a prognostic biomarker in future immunotherapy trials.

  • Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study

    by Orhun Akdogan, Sevgi Eryildiz Yucel, Ozan Yazici, Kadriye Bir Yucel, Fatih Gurler, Galip Can Uyar, Gözde Savas, Enes Yesilbas, Ugur Coskun, Kadriye Baskurt, et al.

    PURPOSE: Capecitabine-induced hand-foot syndrome (HFS) is a frequent toxicity that impairs quality of life and may require chemotherapy dose modification. Although prophylactic topical diclofenac showed benefit in a randomized trial, its effectiveness in routine clinical practice remains uncertain. We evaluated the real-world effectiveness of topical diclofenac for prevention of clinically significant capecitabine-induced HFS. METHODS: DICLO-HFS was a prospective, two-center observational study conducted in Türkiye between July 2023 and February 2024. Adults with colorectal or gastric cancer receiving capecitabine-based therapy were managed with either prophylactic 1% topical diclofenac twice daily or active monitoring according to routine practice. HFS was assessed weekly using Common Terminology Criteria for Adverse Events v5.0 by physicians not involved in treatment allocation. The primary end point was incidence of grade ≥2 HFS. Secondary end points included time to onset of grade ≥2 HFS and capecitabine dose reductions attributable to HFS. RESULTS: A total of 151 patients were included (71 diclofenac; 80 active monitoring). During a median follow-up of 19.1 weeks, grade ≥2 HFS occurred in 12 (16.9%) of 71 patients receiving diclofenac and 11 (13.8%) of 80 patients under active monitoring (odds ratio [OR], 1.28 [95% CI, 0.52 to 3.10]; P = .591). Time to onset did not differ between groups (log-rank P = .392). HFS-related dose reductions occurred in 24 (33.8%) of 71 and 20 (25.0%) of 80 patients, respectively (OR, 1.53 [95% CI, 0.76 to 3.10]; P = .235). In multivariable analysis, female sex and capecitabine monotherapy were independently associated with grade ≥2 HFS. CONCLUSION: In this prospective real-world study, prophylactic topical diclofenac did not reduce clinically significant capecitabine-induced HFS or delay its onset compared with active monitoring. These findings do not support routine diclofenac prophylaxis in everyday practice.

  • Key Methodological Considerations in the Interpretation of the CONKO-007 Trial

    by Orhun Akdogan, Ahmet Ozet, Ozan Yazıcı, Nuriye Ozdemir, Osman Sütcüoglu


  • Open Access

    Clinicopathological Features of Intrahepatic Cholangiocarcinoma with Assessment of IDH1 Mutation: A Two-Center Retrospective Study

    by Muge Buyukaksoy, Selin Akturk Esen, Nesrin Turhan, Enes Seyda Sahiner, Imdat Eroglu, Aysenur Sert, Ugur Ozberk, Denizcan Hasturk, Oznur Bal, Efnan Algin, et al.

    Background/Objective: Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive malignancy with limited therapeutic options and poor survival outcomes. Recent advances in molecular oncology have highlighted the significance of isocitrate dehydrogenase 1 (IDH1) mutations as potential therapeutic targets. However, data on the prevalence and prognostic implications of IDH1 mutations in patients with iCCA are scarce. This study aimed to retrospectively investigate the IDH1 mutation rate, histopathological features, and survival outcomes of patients with iCCA. Methods: We retrospectively analyzed 88 patients diagnosed and treated between 2005 and 2025 at two tertiary oncology centers. Clinical, pathological, and survival data were obtained from the institutional oncology archives and national population databases. IDH1 mutation status was evaluated using polymerase chain reaction and next-generation sequencing of paraffin-embedded tissue samples. Results: A total of 88 patients with iCCA were included, with a median age of 62 years, and 62.5% were male. Abdominal pain was the most common presenting symptom (67%). The most frequent stages at diagnosis were stage IB and stage IIIB (22.7% each). Histopathologically, the small-duct subtype (55.7%), nodular morphology (67.0%), and solitary tumors (79.5%) predominated. IDH1 mutation was detected in 2.3% of patients. Curative surgery was performed in 78.2% of cases and was more common in early-stage disease. Gemcitabine–capecitabine was the most frequently used adjuvant regimen, whereas gemcitabine–cisplatin was the most common palliative treatment regimen. Median overall survival differed significantly by albumin-bilirubin (ALBI) grade, with 40.1, 11.1, and 4.4 months for grades 1, 2, and 3, respectively (p < 0.001). Conclusions: In this multicenter cohort, iCCA was characterized by diverse clinicopathological features and treatment approaches. Surgical resection remains the main treatment modality for patients with localized disease, whereas systemic therapies are more frequently used in advanced stages. The findings highlight the prognostic relevance of baseline clinical and biochemical characteristics and may improve risk stratification in patients with iCCA.

  • Late toxicity after IMRT for head and neck cancer and its predictors in routine practice: A retrospective single-center cohort study

    by Orhun Akdogan, Gonca Altinisik Inan, Nuriye Ozdemir, İbRahim Karadag, Kursat Dal, Emin Gemicioglu, Talip Yigit, Neslihan Ozturk, Naim Ata

    Aim: Late toxicities remain a major determinant of long-term morbidity after intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC). However, the relative contribution of patient- and treatment-related predictors in routine clinical practice remains insufficiently characterized. This study aimed to evaluate factors associated with late toxicity burden in IMRT-treated HNC patients. Methods: We conducted a retrospective single-center cohort study including HNC patients treated with IMRT. Late toxicities occurring at least 90 days after radiotherapy were graded according to CTCAE v5.0. Dysphagia, mucositis, dermatitis, and xerostomia were evaluated, and a composite toxicity burden score was generated by summing the four toxicity domains. Clinical, treatment- related, and smoking-related variables were analyzed using univariable statistical methods and exploratory CHAID decision-tree models. Results: A total of 220 patients were included in the final analysis. Mean age was 59.82±11.7 years, and 80.91% of patients were male. Grade 2 dysphagia and mucositis were observed in 40.45% and 40.91% of patients, respectively, while most patients experienced grade 0 dermatitis and xerostomia. Higher composite toxicity burden was significantly associated with total radiation dose, irradiation time per fraction, body mass index, smoking exposure, concurrent chemotherapy, and smoking status (all p<0.05). In exploratory CHAID analyses, smoking status consistently emerged as the most influential predictor of toxicity burden. Conclusion: Smoking exposure was the strongest predictor of late toxicity burden in IMRT-treated HNC patients, with additional contributions from treatment intensity and concurrent chemotherapy. These findings emphasize the importance of incorporating detailed smoking history into late-toxicity risk stratification and survivorship planning in patients undergoing IMRT for HNC.

  • Open Access

    Evaluation of Clinical, Pathological, and Treatment Effects on Prognosis in Non-Metastatic Esophagus Squamous Cell Carcinoma

    by Hatice Zeynep Dikici, Nuriye Özdemir, Selma Özkan Karaahmetoğlu

    Objective: This study analyzed demographic, clinical, and pathological features, treatment responses, and survival outcomes in non-metastatic esophageal SCC patients. Methods: A retrospective review of 74 patients was conducted. Performance status was assessed using ECOG, treatment response via RECIST 1.1, and staging via AJCC 7th edition TNM. Results: The male-to-female ratio was 0.95, with a mean age of 50.6. Tumors were mainly distal (58%), and most patients (68.7%) presented at stage 2 (25%) or 3 (43.7%). Surgery was performed in 64.9% (47.3% surgery only, 35.1% CRT only, 17.6% CRT + surgery). Median overall and disease-free survival were 38 and 24 months, respectively. Female gender, middle/lower tumor location, fewer metastatic lymph nodes, and CRT + surgery correlated with better survival (p < 0.05). Conclusion: Surgery was the most common treatment, but CRT + surgery yielded superior survival. Local recurrence was more frequent than distant metastasis. A combined approach is crucial for optimal outcomes.

  • Open Access

    Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study

    by Osman Sütcüoğlu, Orhun Akdoğan, İlknur Deliktaş Onur, Atilla Çiftçi, Ali Alkan, Nargiz Majidova, Elif Şahin, Gül Sema Yıldıran, Elif Şenocak Taşçı, Gözde Kavgacı, et al.

    This study aims to evaluate the effectiveness and real-world applicability of total neoadjuvant therapy (TNT) in patients with locally advanced rectal cancer (LARC), focusing on pathological complete response (pCR) and disease-free survival (DFS) across different chemotherapy regimens. In this multicenter retrospective study, patients treated between January 2019 and January 2023, 437 patients with locally advanced rectal cancer who underwent total neoadjuvant therapy followed by surgery were analyzed. Standard fluoropyrimidine-based chemotherapy regimens (CAPOX, FOLFOX, or FOLFIRINOX) were used according to institutional practice, and long-course chemoradiotherapy constituted the predominant radiotherapy approach. Patients were grouped based on chemotherapy sequencing as induction, consolidation, or sandwich regimens. Outcomes were evaluated using multivariable logistic regression for pathological complete response and Kaplan–Meier analysis with Cox proportional-hazards modeling for disease-free survival. The median follow-up duration was 66 months. The overall pCR rate was 26.3% (n = 115). pCR rates did not differ significantly between induction, sandwich, and consolidation chemotherapy regimens. A longer interval (> 8 weeks) between radiotherapy and surgery was associated with a higher likelihood of achieving pCR. In contrast, cT4 disease and baseline CEA levels > 3 ng/mL were associated with lower pCR rates.The estimated 3-year disease-free survival (DFS) rate was 83.8%. Recurrence rates within 3 years were numerically higher in patients receiving induction and sandwich regimens compared with consolidation chemotherapy, although these differences did not reach statistical significance. In multivariable analysis, poor tumor regression grade, ypT4 stage, ypN + disease, and post-TNT CEA ≥ 3 ng/mL were independently associated with an increased risk of recurrence. TNT is effective and feasible in real-world settings, achieving pCR and DFS outcomes comparable to clinical trials. No statistically significant differences were observed in pCR or recurrence rates between induction, consolidation, and sandwich chemotherapy regimens. Prospective phase III trials are needed to compare DFS and OS outcomes across these treatment strategies. The online version contains supplementary material available at 10.1007/s12672-026-04842-3.

  • Clinical Features and Survival Outcomes in Primary Intestinal Lymphoma: A Multicenter Retrospective Study

    by Merve Turan, Nuriye Özdemir, Mehmet KüçÜkÖner, Asude Aksoy, Hilmi Kodaz, Mesut Şeker

    Ejmi Eurasian Journal of Medical Investigation